Helus Pharma Announces Positive Topline Results from Phase 3 APPROACH Study evaluating HLP003 as Adjunctive Treatment in Major Depressive Disorder November 16, 2026 | 8:00 AM EST Webcast Supporting Materials Topline Presentation